WILMINGTON – Seeking to supercharge its cancer drug pipeline, pharmaceutical giant AstraZeneca announced a deal potentially worth more than $1.2 billion to acquire a small California-based biotech firm working on lymphoma treatment. AstraZeneca, which has ...